Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2015', provides an overview of the Herpes Labialis (Oral Herpes)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Herpes Labialis (Oral Herpes) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Labialis (Oral Herpes) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9
Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10
Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11
Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Herpes Labialis (Oral Herpes) - Products under Development by Companies 15
Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17
Beech Tree Labs, Inc. 17
Foamix Pharmaceuticals Ltd. 18
Mymetics Corporation 19
NanoViricides, Inc. 20
Onxeo SA 21
Shulov Innovative Science Ltd. 22
TGV-Laboratories 23
Herpes Labialis (Oral Herpes) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
acyclovir - Drug Profile 33
Mechanism of Action 33
R&D Progress 33
acyclovir - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Aspidasept - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
BTL-TMLHSV - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Herpecide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
herpes simplex virus [type 1, 2] vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
herpes simplex virus [type 1, 2] vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Teg-379 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ZEP-3 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 43
Herpes Labialis (Oral Herpes) - Dormant Projects 46
Herpes Labialis (Oral Herpes) - Discontinued Products 47
Herpes Labialis (Oral Herpes) - Product Development Milestones 48
Featured News & Press Releases 48
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 48
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 48
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 49
Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 49
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 50
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 51
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 51
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 52
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 52
Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Herpes Labialis (Oral Herpes), H2 2015 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H2 2015 17
Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 18
Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H2 2015 19
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H2 2015 20
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H2 2015 21
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd., H2 2015 22
Herpes Labialis (Oral Herpes) - Pipeline by TGV-Laboratories, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H2 2015 43
Herpes Labialis (Oral Herpes) - Dormant Projects, H2 2015 46
Herpes Labialis (Oral Herpes) - Discontinued Products, H2 2015 47